Advertisement

Current state of the art in continuous bioprocessing

  • Mark Schofield
Review

Abstract

There is an upsurge of interest in continuous bioprocessing, but currently continuous downstream bioprocessing has not been implemented to generate clinical material. This review focusses on the current state of the art of continuous downstream processing, highlighting the key advantages over traditional batch manufacturing. This allows the identification of scenarios where continuous downstream processing may be critical for commercial manufacturing success.

Keywords

Continuous downstream processing Bioprocess intensification Clinical manufacturing 

References

  1. Alsaab H, Sau S, Alzhrani R et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561CrossRefPubMedPubMedCentralGoogle Scholar
  2. Association Alzheimer’s (2016) Alzheimer’s disease facts and figures. Alzheimers Dement 12(4):459–509CrossRefGoogle Scholar
  3. Bell D, Dunnill P, Esser K, Flaschel E, Hoare M, Holló J, Kula M-R, Lang-Hinrichs C, Nyeste L, Pécs M, Sevella B (2013) Downstream processing. Springer, New YorkGoogle Scholar
  4. Biopharm International, Outsourcing resources 2017Google Scholar
  5. BioPlan White Paper (2015) Continuous bioprocessing: industry demanding more data to make decisions. BioPlan Associates Inc, RockvilleGoogle Scholar
  6. Bisschops M, Brower M (2013) The impact of continuous multicolumn chromatography on biomanufacturing efficiency. Pharm Bioprocess 1(4):361–372CrossRefGoogle Scholar
  7. Bisschops M, Frick L, Fulton S, Ransohoff T (2009) Single-use, continuous-countercurrent, multicolumn chromatography. BioProcess Int 7:S18–S23Google Scholar
  8. Boedeker B (2001) Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost 27(4):385–394CrossRefPubMedGoogle Scholar
  9. Boedeker B, Magnus J (2017) Opportunities and limitations of continuous processing and use of disposables. Am Pharm Rev 20(1)Google Scholar
  10. Brower M, Pollard D, Hung F (2015) Protein Refinery Operations Lab (PRO Lab): a sandbox for continuous protein production & advanced process control. Proceedings of integrated continuous biomanufacturing II. http://dc.engconfintl.org/biomanufact_ii/82/
  11. Clapperton R (2001) Practical use of continuous processing in developing and scaling up. Org Process Res Dev 5(6):613–621CrossRefGoogle Scholar
  12. Dörner T, Kay J (2015) Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 11(12):713–724CrossRefPubMedGoogle Scholar
  13. Fletcher H (2010) Turn batch to continuous processing. Manuf Chem 24–26. https://www.manufacturingchemist.com/news/article_page/Turn_batch_to_continuous_processing/54954
  14. Godawat R, Konstantinov K, Rohani M, Warikoo V (2015) End-to-end integrated fully continuous production of mAbs. J Biotechnol 213:13–19CrossRefPubMedGoogle Scholar
  15. Goudar C, Domach M (2017) Special section on continuous bioprocessing and welcome professor Liu to the editorial board. Biotechnol Progr 33:853CrossRefGoogle Scholar
  16. Hammerschmidt N, Tscheliessnig A, Sommer R, Helk B, Jungbauer A (2014) Economics of recombinant antibody production processes at various scales: industry-standard compared to continuous precipitation. Biotechnol J 9:766–775CrossRefPubMedGoogle Scholar
  17. Hernandez R (2017) Unifying continuous biomanufacturing operations. BioPharm Int 30(6):14–19Google Scholar
  18. Hummel J, Pagkaliwangan M, Gjoka X, Davidovits T, Stock R, Ransohoff T, Gantier R, Schofield M (2018) Modeling the downstream processing of monoclonal antibodies reveals cost advantages for continuous methods for a broad range of manufacturing scales. Biotechnol J.  https://doi.org/10.1002/biot.201700665 PubMedGoogle Scholar
  19. James F, Leslie W, Heather S, Kate L, Alvydas M, John O, Jeff S (2016) First-inhuman, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement 2:169–176Google Scholar
  20. Kelley B (2009) Industrialization of mAb production technology. The bioprocessing industry at a crossroads. mAbs 1(5):443–452CrossRefPubMedPubMedCentralGoogle Scholar
  21. Klutz S, Magnus J, Lobedann M, Schwan P, Maiser B, Niklas J, Temming M, Schembecker G (2015) Developing the biofacility of the future based on continuous processing and single-use technology. J Biotechnol 213:120–130CrossRefPubMedGoogle Scholar
  22. Konstantinov K, Cooney C (2015) White paper on continuous bioprocessing. J Pharm Sci 104(3):813–820CrossRefGoogle Scholar
  23. Laird T (2007) Continuous processes in small-scale manufacture. Org Process Res Dev 11(6):927CrossRefGoogle Scholar
  24. Lansing SD (1920) The paper machine—its history and future development. Pap Mak J 20:17–21Google Scholar
  25. Levine H, Stock R, Lilja J, Gaasvik A, Hummel H, Ransohoff T, Jones SD (2013) Single-use technology and modular construction. Biopharm International 11(4):40–45Google Scholar
  26. Okazaki T, Honjo T (2006) The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27:195–201CrossRefPubMedGoogle Scholar
  27. Ozturk S (2014) Opportunities and challenges for the implementation of continuous processing in biomanufacturing. Wiley, New YorkCrossRefGoogle Scholar
  28. Pearson S (2006) Multiproduct manufacturing facilities: despite contamination and compliance concerns, flexibility remains the key driver. Genet Eng News 26:42–43Google Scholar
  29. Piachaud B (2002) Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience. Technovation 22(2):81–90CrossRefGoogle Scholar
  30. Poggioli G, Laureti S, Campieri M et al (2007) Infliximab in the treatment of Crohn’s disease. Ther Clin Risk Manag 3(2):301–308CrossRefPubMedPubMedCentralGoogle Scholar
  31. Pollard D, Brower M, Abe Y, Lopes A, Sinclair A (2017) Standardized economic cost modeling for next-generation MAb production. Bioprocess Int 14(8):14–23Google Scholar
  32. Pollard D, Brower M, Richardson D (2018) Progress toward automated single-use continuous monoclonal antibody manufacturing via the protein refinery operations lab. Continuous biomanufacturing—innovative technologies and methods: innovative technologies and methods. Wiley-VCH Verlag GmbH & Co, WeinheimGoogle Scholar
  33. Pollock J, Coffman J, Ho SV, Farid SS (2017) Integrated continuous bioprocessing: economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnol Prog 33(4):854–866CrossRefPubMedPubMedCentralGoogle Scholar
  34. Reay D, Ramshaw C, Harvey A (2008) Process intensification: engineering for efficiency, sustainability and flexibility. Butterworth-Heinemann, OxfordGoogle Scholar
  35. Steiner R, Jornitz M (2017) Continuous processing in the pharmaceutical industry: status and perspective. Wiley, New YorkGoogle Scholar
  36. Thomas H (2008) Batch-to-continuous—coming out of age. Chem Eng 805:38–45Google Scholar
  37. Walther J, Godawat R, Hwang C, Abe Y, Sinclair A, Konstantinov K (2015) The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. J Biotechnol 213:3–12CrossRefPubMedGoogle Scholar
  38. Warikoo V, Godawat R, Brower K, Jain S, Cummings D, Simons E, Johnson T, Walther J, Yu M, Wright B, McLarty J, Karey K, Hwang C, Zhou W, Riske F, Konstantinov K (2012) Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng 109:3018–3029CrossRefPubMedGoogle Scholar
  39. Zhu M, Mollet M, Hubert R (2012) Industrial production of therapeutic proteins: cell lines, cell culture, and purification. In: Kent J (ed) Handbook of industrial chemistry and biotechnology. Springer, BostonGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Pall BiotechWestboroughUSA

Personalised recommendations